Phase 2 Study of Gemcitabine in Combination With Rituximab in Patients With Recurrent or Refractory Hodgkin Lymphoma.

The article focuses on a study which aims to investigate the activity of gemcitabine in combination with rituximab in individuals with recurring or refractory Hodgkin lymphoma (HL). It cites that the malignant Hodgkin and Reed-Sternberg (HRS) cells of HL express various receptors that belong to the tumor necrosis factor (TNF) receptor family, such as CD40, CD30 and exogenous soluble CD40 ligand. It notes that gemcitabine in combination with rituximab generated an overall response rate of 48% in individuals with recurring or refractory HL.